Malignant infantile osteopetrosis (MIOP) is a rare hereditary disorder of osteoclast function, which can be reversed by hematopoietic stem cell transplantation (SCT). We observed a high incidence of hepatic veno-occlusive disease (VOD) in transplanted patients and explored the prevention of this complication by using defibrotide (DF) as a prophylaxis. Twenty children with MIOP were consecutively transplanted in our center between 1996 and 2005. Eleven of these patients were transplanted between 1996 and 2001 and experienced an overall incidence of VOD of 63.6% (7/11). VOD was severe in three patients and one patient succumbed to VOD-related multi-organ failure. Owing to this very high incidence of VOD, DF prophylaxis was initiated in nine patients consecutively transplanted between 2001 and 2005. In this group, only one patient (11.1%) was diagnosed with moderate VOD. We report here a very high risk in patients with MIOP to develop VOD after transplantation. Prophylactic DF was implemented in our current transplant protocol and reduced the VOD rate significantly in this high-risk population.
Introduction
Malignant infantile osteopetrosis (MIOP), inherited in an autosomal recessive pattern (incidence estimated at 1:200 000) is characterized by a generalized increase in bone density. 1 In 50-60% of patients, MIOP is caused by mutations in the gene coding for the A3 subunit of the osteoclast vacuolar H þ -ATPase proton pump (TCIRG1). [2] [3] [4] Mutations affecting the osteoclast-specific chloride channel (CLCN7) occur in 10-15% of patients with severe autosomal recessive MIOP. [5] [6] [7] The functional deficiency of osteoclastic bone resorption in MIOP results in imbalanced bone deposition with consecutive medullary hematopoietic insufficiency, extramedullary hematopoiesis and sensoneural impairment. MIOP most frequently presents with hypocalcemia, convulsions and/or visual impairments in the first months of life followed by hepatosplenomegaly, cytopenias and fractures.
As in most variants of MIOP the defect is intrinsic to the osteoclast which are of hematopoietic origin, the disorder can be reversed by hematopoietic stem cell transplantation (SCT). 8, 9 SCT in MIOP is associated with major lifethreatening complications including pulmonary hypertension and hepatic veno-occlusive disease (VOD) especially when using alternative donors. 10, 11 Severe VOD with multi-organ failure (MOF) is associated with a very high mortality. 12, 13 Defibrotide (DF) is a single-stranded polydeoxyribonucleotide derived from porcine tissue, which possesses anti-thrombotic, thrombolytic, anti-inflammatory and antiischemic properties. In preclinical studies, DF exerted a protective effect on injured microvasculature. [14] [15] [16] [17] [18] Early retrospective clinical trials of DF in mostly adult patients who fulfilled criteria for severe VOD based on the presence of MOF demonstrated encouraging responses. 19, 20 A singlearm cohort study 21 and a prospective randomized trial of mostly adult patients with severe VOD confirmed these findings, clearly indicating efficacy of DF in the treatment of severe VOD. 22 A recent retrospective study on 45 children with VOD demonstrated in the subgroup of 22 patients with severe disease that younger age and early start of therapeutic DF was associated with a significantly superior outcome. 23 The diagnosis of VOD still relies on a combination of clinical signs such as hepatomegaly, right upper quadrant pain, ascites, weight gain and hyperbilirubinemia summarized in the Baltimore 24 or Seattle criteria. 12 The sensitivity of those criteria is poor 25 and reliable laboratory tests or imaging tools to diagnose VOD early are not available. The lack of reliable diagnostic tools to identify VOD early impedes pre-emptive therapeutic intervention. Prophylactic use of DF in a high-risk pediatric population is therefore an encouraging modality supported by two small series 26, 27 and the benign adverse event profile. 19, 20, 22, 23 We report a single center experience in patients transplanted for MIOP, where we observed a high rate of hepatic VOD, which was reduced significantly in patients who received DF prophylaxis.
Patients and methods

Patients
Enrolled in the analysis were 20 patients of less than 2 years of age diagnosed with MIOP who received an allogeneic SCT after approval was obtained from the research ethical committee. The demographic and SCT data were collected from the pediatric SCT database and medical records. The following data were collected: baseline weight, daily weights for the entire duration of hospitalization, day of the first bilirubin value of more than 34.2 mmol/l (2 mg/dl), day of first sign of hepatomegaly or right upper quadrant pain, age at time of SCT, disease status at time of SCT, donor type (allogeneic matched related donor (MRD), allogeneic mismatched related donor (MMRD)), human lymphocyte antigen matching, serum transaminases, hepatitis serology before transplant, conditioning regimen and use of heparin prophylaxis. Data on the clinical course and treatment were collected from patients with a diagnosis of VOD, including baseline and maximum value for total serum bilirubin, pulmonary and renal function data and maximum serum ammonia level. Routine low-dose heparin (100 IU/kg/day) was used for all patients. Patients with the diagnosis of VOD, regardless of severity, were treated according to standard supportive care measures with the goal to reduce pain, maintain kidney perfusion and limit fluid retention.
Methods DF administration, dose calculation and toxicity. DF was administered intravenous (i.v.) in D5W (dextrose 5% in water) in four divided doses daily over 2-4 h. Patients on the prophylaxis arm started on the day of conditioning. If VOD was not diagnosed, DF was discontinued on day þ 30 post SCT. The total dose, the duration of treatment and the weight were recorded. The DF dose was calculated in mg/kg/day and rounded to the nearest 5 mg. Toxicity is reported according to standard common toxicity criteria. Therapeutic DF was administered until there was complete resolution of ascites, reversion of hepatopedal flow and normalization of the total and direct bilirubin.
Criteria for the diagnosis of VOD and assessment of the severity of disease. Patients were diagnosed with VOD based on the Seattle criteria. 24 Other causes for the observed signs and symptoms were excluded by clinical assessment at the time of diagnosis of VOD. Mild and moderate VOD were defined retrospectively according to established criteria. 12 Severe VOD was based on the presence of MOF in addition to VOD, defined as either an oxygen requirement with an oxygen saturation of o90% on room air and/or ventilator dependence and/or renal dysfunction (defined as doubling of baseline creatinine and/or dialysis dependence) and/or encephalopathy. 20 In order for MOF to be VOD-related, it had to be present within 28 days after the diagnosis of VOD. Complete remission was defined as resolution of VOD-and MOFrelated symptoms together with a bilirubin decrease to less than 34.2 mmol/l (2 mg/dl).
Statistical analysis
Statistical analysis included the two-tailed Fisher exact test for independent categorical variables and the Wilcoxon test for independent continuous variables. All data analyses were performed using the statistical analysis software SAS (Version 9.1; SAS Institute Inc., Cary, NC, USA).
Results
Patient and SCT characteristics
The observation period ranged from January 1996 to May 2005. A total of 20 consecutive patients with MIOP, 14 females and six males undergoing SCT with a median age of 5 months (range 1-21 months) were included in this retrospective analysis. The underlying molecular defect was identified in 18 patients (90%) and consisted of a homozygous TCIRG1 mutation in 11 patients (61%), a heterozygous TCIRG1 mutation in three patients (17%) and a compound heterozygous TCIRG1 mutation in four patients (22%). In two patients (10%), none of the known MIOP-related mutations were identified (Table 1) .
Eight patients received an unmanipulated bone marrow graft, either from a MRD (n ¼ 7) or a matched unrelated donor (n ¼ 1), and 12 patients received a T-cell-depleted peripheral blood stem cell graft from a haploidentical donor (MMRD) ( Tables 1 and 2 ). Conditioning before HSCT was variable. Whereas busulfan (either oral or i.v.) was used in all patients, cyclophosphamide, fludarabine and thiotepa were given in different combinations (Tables 1  and 2 ). In the majority of patients transplanted between January 1996 and March 2001, the conditioning included thiotepa, which was omitted in subsequently transplanted patients. In addition, nine of these latter patients received DF prophylaxis.
Patients with and without DF prophylaxis were not significantly different concerning age at diagnosis, time to transplant (age at SCT), weight, sex, type of graft and donor and the disease status reflected in the hematopoietic status at SCT (anemia and thrombocytopenia). The underlying molecular diagnoses were also comparable between the two groups and the historical control group differed only with the use of thiotepa for conditioning (Table 1) .
DF: administration, dose and duration of use DF was administered for a median of 42 days (mean: 44 days, range 31-74 days, including the one patient with therapeutic DF). The median DF dose was 40 mg/kg/day (mean: 32.2 mg/kg/day, range 20-40 mg/kg/day). The patient in the prophylaxis group who developed a moderate VOD was treated with 20 mg/kg/day for 25 days as prophylaxis and was increased then to 60 mg/kg/day for 49 days. Standard measures like low-dose heparin (100 U/kg/day) were not discontinued during therapeutic DF (Table 1) . 
Outcome
The overall survival was 85% (17/20) . The overall incidence of VOD was 40% (8/20) with 63.6% (7/11) in the historical control group and 11.1% (1/9) in the DF prophylaxis group (0.028; Fisher exact). Mild and moderate VOD was diagnosed in four out of seven patients and severe VOD occurred in three out of seven patients in the historical control group. In the prophylaxis group, one patient developed moderate VOD and required only supportive care ( Figure 1 and Table 2 ). Two of the three patients with severe VOD in the historical control group were admitted to intensive care for a total duration of 54 days. The overall mortality was 18.2% (2/11) in the historical control group and 11% (1/9) in the prophylaxis group. One patient in the historical control group succumbed to VOD-related MOF. The second patient in the historical control group and one patient in the prophylaxis group died of complications secondary to graft rejection (Tables 1 and 2 ). DF was tolerated very well and no adverse events were observed. Prophylactic DF did not influence the incidence of infectious complications, graft-versus-host disease (GVHD) and the long-term outcome. The incidence of VOD within the historical control group was equally distributed between the patients who were transplanted with and without thiotepa (1.0; Fisher exact). There was also no coincidence between VOD and the age of the patients (0.64; Fisher exact; comparing age less than 6 months and over 6 months).
Discussion
Along with GVHD and cytomegalovirus infection, VOD is one of the major complications of SCT. The overall incidence of VOD in children was recently reported between 10 and 30%. 28, 29 We analyzed the outcomes of a group of 20 patients with MIOP transplanted in a single center. With 63.6%, we observed a very high incidence of VOD in infants and toddlers undergoing SCT. Also the morbidity in this historical control group with three patients (43%) developing severe VOD with MOF and two admissions to the ICU owing to VOD-related MOF was exceedingly high. In a group of nine patients who were consecutively transplanted with DF prophylaxis and without thiotepa, only one patient developed moderate VOD (11.1%) and was treated with standard supportive measures.
A major limitation of the study is the nonrandomized design with a historical control arm. We intended to compensate this weakness and compared well-matched groups of patients. We limited the inclusion period to the most recent years in order to reduce the bias owing to progress in SCT, and hypothesized that myeloablative conditioning regimens in infants younger than 6 months could be a risk factor for VOD but found no correlation. The variety of TCIRG1 mutations in MIOP made a correlation of the genotype with the incidence of VOD impossible. Inasmuch the disease itself or a particular molecular variant raises the risk to develop VOD during SCT can currently not be answered.
We suspected that thiotepa, an alkylating agent might be responsible for the high incidence of VOD in infants transplanted with a myeloablative regimen. In order to limit any thiotepa-related risk for VOD in patients with MIOP, we removed thiotepa from the conditioning regimen. Therefore, thiotepa was next to DF the only other factor unequally distributed between the two groups and that could have impacted on the high incidence of VOD. But within the group of patients who received thiotepa as part of the conditioning regimen, the incidence of VOD was not different. There is very little information in the literature on a possible correlation between thiotepa and VOD especially in children. But pediatric conditioning regimens containing thiotepa were not reported to have an exceedingly high incidence of VOD. [30] [31] [32] [33] Most recently a treatment regimen consisting of cyclophosphamide, thiotepa and carboplatin was assessed for the occurrence of VOD in adults. The calculated plasma concentration-time curves (AUCs) for cyclophosphamide and its activated metabolites showed that the incidence of VOD was rather linked to bioactivated cyclophosphamide than to the administration of thiotepa. 34 Nevertheless, based on this study we cannot exclude with certainty the influence of thiotepa on the incidence of VOD in the historical control group. DF prophylaxis was introduced for several reasons. The clinical criteria and the available imaging techniques as well as laboratory parameters are too insensitive for an early diagnosis of VOD. Several clinical trials of DF in patients with severe VOD demonstrated encouraging responses. [19] [20] [21] [22] DF has reportedly few adverse effects and most importantly, we observed a significantly superior outcome in severe VOD with therapeutic DF in younger patients when treatment was initiated immediately after diagnosis. 23 In our hands DF was tolerated very well, the four-timesa-day administration of DF was feasible and no adverse or serious adverse events were reported.
Our results confirm earlier observations that the risk to develop severe VOD in patients transplanted for MIOP is very high. 10 ,11 DF appears to provide effective protection in patients with MIOP from developing SCT-related VOD. Therefore, prophylactic DF could be implemented in current transplant protocols and might be beneficial in a high-risk pediatric population. Inasmuch as prophylactic DF is superior to therapeutic DF with regard to reducing morbidity and mortality, avoiding the need of an ICU transfer, dialysis and other costly therapeutic measures cannot be answered with this group of patients as the historical control arm did not receive therapeutic DF. A prospective randomized international multi center trial designed to answer the question of whether prophylactic DF is superior to therapeutic DF in children at high risk to develop VOD during SCT is open for recruitment (NIH Trial Number: NCT00272948).
